APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Biologics for Severe Asthma

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Biologics for Severe Asthma Market Outlook and Growth Opportunities 2026

Report ID 173970750429 December 2025199 pages

Choose your research edition.

Industry ResearchBiologics for Severe Asthma Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics for Severe Asthma Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Biologics for Severe Asthma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics for Severe Asthma Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics for Severe Asthma Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Biologics for Severe Asthma market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Biologics for Severe Asthma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biologics for Severe Asthma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biologics for Severe Asthma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Biologics for Severe Asthma market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Biologics for Severe Asthma market include Teva Pharmaceuticals, Sanofi, Novartis, Roche, Regeneron Pharmaceuticals, GSK, AstraZeneca and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Biologics for Severe Asthma market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biologics for Severe Asthma and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biologics for Severe Asthma sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biologics for Severe Asthma market size, projected growth trends, production technologies, key applications, and end-use industries.

Biologics for Severe Asthma Segment by Company

Teva Pharmaceuticals

Sanofi

Novartis

Roche

Regeneron Pharmaceuticals

GSK

AstraZeneca

Amgen

Biologics for Severe Asthma Segment by Type

Omalizumab

Benralizumab

Dupirumab

Mepolizumab

Reslizumab

Tezepelumab-ekko

Biologics for Severe Asthma Segment by Application

Clinic

Hospital

Other

Biologics for Severe Asthma Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biologics for Severe Asthma status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Biologics for Severe Asthma market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biologics for Severe Asthma significant trends, drivers, influence factors in global and regions.

6. To analyze Biologics for Severe Asthma competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics for Severe Asthma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics for Severe Asthma and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics for Severe Asthma.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biologics for Severe Asthma market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologics for Severe Asthma industry.

Chapter 3: Detailed analysis of Biologics for Severe Asthma manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Biologics for Severe Asthma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Biologics for Severe Asthma in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biologics for Severe Asthma Industry Trends Table 2. Biologics for Severe Asthma Industry Drivers Table 3. Biologics for Severe Asthma Industry Opportunities and Challenges Table 4. Biologics for Severe Asthma Industry Restraints Table 5. Global Biologics for Severe Asthma Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biologics for Severe Asthma Revenue Share by Company (2021-2026) Table 7. Global Biologics for Severe Asthma Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Biologics for Severe Asthma Sales Volume Share by Company (2021-2026) Table 9. Global Biologics for Severe Asthma Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Biologics for Severe Asthma Company Ranking, (2024-2026) & (USD Million) Table 11. Global Biologics for Severe Asthma Key Company Manufacturing Base & Headquarters Table 12. Global Biologics for Severe Asthma Company, Product Type & Application Table 13. Global Biologics for Severe Asthma Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Biologics for Severe Asthma by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Omalizumab Table 18. Significant Companies of Benralizumab Table 19. Significant Companies of Dupirumab Table 20. Significant Companies of Mepolizumab Table 21. Significant Companies of Reslizumab Table 22. Significant Companies of Tezepelumab-ekko Table 23. Global Biologics for Severe Asthma Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Biologics for Severe Asthma Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Biologics for Severe Asthma Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Biologics for Severe Asthma Sales Volume Share by Type (2021-2026) Table 27. Global Biologics for Severe Asthma Sales Volume Share by Type (2027-2032) Table 28. Global Biologics for Severe Asthma Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Biologics for Severe Asthma Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Biologics for Severe Asthma Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Biologics for Severe Asthma Sales Value Share by Type (2021-2026) Table 32. Global Biologics for Severe Asthma Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Clinic Table 34. Significant Companies of Hospital Table 35. Significant Companies of Other Table 36. Global Biologics for Severe Asthma Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Biologics for Severe Asthma Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Biologics for Severe Asthma Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Biologics for Severe Asthma Sales Volume Share by Application (2021-2026) Table 40. Global Biologics for Severe Asthma Sales Volume Share by Application (2027-2032) Table 41. Global Biologics for Severe Asthma Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Biologics for Severe Asthma Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Biologics for Severe Asthma Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Biologics for Severe Asthma Sales Value Share by Application (2021-2026) Table 45. Global Biologics for Severe Asthma Sales Value Share by Application (2027-2032) Table 46. Global Biologics for Severe Asthma Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Biologics for Severe Asthma Sales by Region (2021-2026) & (K Units) Table 48. Global Biologics for Severe Asthma Sales Market Share by Region (2021-2026) Table 49. Global Biologics for Severe Asthma Sales by Region (2027-2032) & (K Units) Table 50. Global Biologics for Severe Asthma Sales Market Share by Region (2027-2032) Table 51. Global Biologics for Severe Asthma Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Biologics for Severe Asthma Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Biologics for Severe Asthma Sales Value Share by Region (2021-2026) Table 54. Global Biologics for Severe Asthma Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Biologics for Severe Asthma Sales Value Share by Region (2027-2032) Table 56. Global Biologics for Severe Asthma Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Biologics for Severe Asthma Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Biologics for Severe Asthma Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Biologics for Severe Asthma Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units) Table 61. Global Biologics for Severe Asthma Sales Market Share by Country (2021-2026) Table 62. Global Biologics for Severe Asthma Sales by Country (2027-2032) & (K Units) Table 63. Global Biologics for Severe Asthma Sales Market Share by Country (2027-2032) Table 64. Global Biologics for Severe Asthma Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Biologics for Severe Asthma Sales Value Market Share by Country (2021-2026) Table 66. Global Biologics for Severe Asthma Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Biologics for Severe Asthma Sales Value Market Share by Country (2027-2032) Table 68. Teva Pharmaceuticals Company Information Table 69. Teva Pharmaceuticals Business Overview Table 70. Teva Pharmaceuticals Biologics for Severe Asthma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Teva Pharmaceuticals Biologics for Severe Asthma Product Portfolio Table 72. Teva Pharmaceuticals Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi Biologics for Severe Asthma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Sanofi Biologics for Severe Asthma Product Portfolio Table 77. Sanofi Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis Biologics for Severe Asthma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Novartis Biologics for Severe Asthma Product Portfolio Table 82. Novartis Recent Development Table 83. Roche Company Information Table 84. Roche Business Overview Table 85. Roche Biologics for Severe Asthma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Roche Biologics for Severe Asthma Product Portfolio Table 87. Roche Recent Development Table 88. Regeneron Pharmaceuticals Company Information Table 89. Regeneron Pharmaceuticals Business Overview Table 90. Regeneron Pharmaceuticals Biologics for Severe Asthma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Regeneron Pharmaceuticals Biologics for Severe Asthma Product Portfolio Table 92. Regeneron Pharmaceuticals Recent Development Table 93. GSK Company Information Table 94. GSK Business Overview Table 95. GSK Biologics for Severe Asthma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. GSK Biologics for Severe Asthma Product Portfolio Table 97. GSK Recent Development Table 98. AstraZeneca Company Information Table 99. AstraZeneca Business Overview Table 100. AstraZeneca Biologics for Severe Asthma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. AstraZeneca Biologics for Severe Asthma Product Portfolio Table 102. AstraZeneca Recent Development Table 103. Amgen Company Information Table 104. Amgen Business Overview Table 105. Amgen Biologics for Severe Asthma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Amgen Biologics for Severe Asthma Product Portfolio Table 107. Amgen Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Biologics for Severe Asthma Distributors List Table 111. Biologics for Severe Asthma Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Biologics for Severe Asthma Product Image Figure 2. Global Biologics for Severe Asthma Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics for Severe Asthma Sales Value (2021-2032) & (US$ Million) Figure 4. Global Biologics for Severe Asthma Sales (2021-2032) & (K Units) Figure 5. Global Biologics for Severe Asthma Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Biologics for Severe Asthma Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Omalizumab Image Figure 10. Benralizumab Image Figure 11. Dupirumab Image Figure 12. Mepolizumab Image Figure 13. Reslizumab Image Figure 14. Tezepelumab-ekko Image Figure 15. Global Biologics for Severe Asthma Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Biologics for Severe Asthma Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Biologics for Severe Asthma Sales Volume Share by Type (2021-2032) Figure 18. Global Biologics for Severe Asthma Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Biologics for Severe Asthma Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Biologics for Severe Asthma Sales Value Share by Type (2021-2032) Figure 21. Clinic Image Figure 22. Hospital Image Figure 23. Other Image Figure 24. Global Biologics for Severe Asthma Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Biologics for Severe Asthma Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Biologics for Severe Asthma Sales Volume Share by Application (2021-2032) Figure 27. Global Biologics for Severe Asthma Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Biologics for Severe Asthma Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Biologics for Severe Asthma Sales Value Share by Application (2021-2032) Figure 30. Global Biologics for Severe Asthma Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Biologics for Severe Asthma Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Biologics for Severe Asthma Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Biologics for Severe Asthma Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Biologics for Severe Asthma Sales Value (2021-2032) & (US$ Million) Figure 35. North America Biologics for Severe Asthma Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Biologics for Severe Asthma Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Biologics for Severe Asthma Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Biologics for Severe Asthma Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Biologics for Severe Asthma Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Biologics for Severe Asthma Sales Value (2021-2032) & (US$ Million) Figure 41. South America Biologics for Severe Asthma Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Biologics for Severe Asthma Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Biologics for Severe Asthma Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Biologics for Severe Asthma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Biologics for Severe Asthma Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Biologics for Severe Asthma Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Omalizumab
  • Benralizumab
  • Dupirumab
  • Mepolizumab
  • Reslizumab
  • Tezepelumab-ekko
Applications
  • Clinic
  • Hospital
  • Other
Companies covered
  • Teva Pharmaceuticals
  • Sanofi
  • Novartis
  • Roche
  • Regeneron Pharmaceuticals
  • GSK
  • AstraZeneca
  • Amgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biologics for Severe Asthma Sales Value (2021-2032)
  4. 1.2.2 Global Biologics for Severe Asthma Sales Volume (2021-2032)
  5. 1.2.3 Global Biologics for Severe Asthma Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Biologics for Severe Asthma Market Dynamics
  1. 2.1 Biologics for Severe Asthma Industry Trends
  2. 2.2 Biologics for Severe Asthma Industry Drivers
  3. 2.3 Biologics for Severe Asthma Industry Opportunities and Challenges
  4. 2.4 Biologics for Severe Asthma Industry Restraints
3 Biologics for Severe Asthma Market by Company
  1. 3.1 Global Biologics for Severe Asthma Company Revenue Ranking in 2025
  2. 3.2 Global Biologics for Severe Asthma Revenue by Company (2021-2026)
  3. 3.3 Global Biologics for Severe Asthma Sales Volume by Company (2021-2026)
  4. 3.4 Global Biologics for Severe Asthma Average Price by Company (2021-2026)
  5. 3.5 Global Biologics for Severe Asthma Company Ranking (2024-2026)
  6. 3.6 Global Biologics for Severe Asthma Company Manufacturing Base and Headquarters
  7. 3.7 Global Biologics for Severe Asthma Company Product Type and Application
  8. 3.8 Global Biologics for Severe Asthma Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Biologics for Severe Asthma Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Biologics for Severe Asthma Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Biologics for Severe Asthma Market by Type
  1. 4.1 Biologics for Severe Asthma Type Introduction
  2. 4.1.1 Omalizumab
  3. 4.1.2 Benralizumab
  4. 4.1.3 Dupirumab
  5. 4.1.4 Mepolizumab
  6. 4.1.5 Reslizumab
  7. 4.1.6 Tezepelumab-ekko
  8. 4.2 Global Biologics for Severe Asthma Sales Volume by Type
  9. 4.2.1 Global Biologics for Severe Asthma Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Biologics for Severe Asthma Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Biologics for Severe Asthma Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Biologics for Severe Asthma Sales Value by Type
  13. 4.3.1 Global Biologics for Severe Asthma Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Biologics for Severe Asthma Sales Value by Type (2021-2032)
  15. 4.3.3 Global Biologics for Severe Asthma Sales Value Share by Type (2021-2032)
5 Biologics for Severe Asthma Market by Application
  1. 5.1 Biologics for Severe Asthma Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Other
  5. 5.2 Global Biologics for Severe Asthma Sales Volume by Application
  6. 5.2.1 Global Biologics for Severe Asthma Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biologics for Severe Asthma Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Biologics for Severe Asthma Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Biologics for Severe Asthma Sales Value by Application
  10. 5.3.1 Global Biologics for Severe Asthma Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Biologics for Severe Asthma Sales Value by Application (2021-2032)
  12. 5.3.3 Global Biologics for Severe Asthma Sales Value Share by Application (2021-2032)
6 Biologics for Severe Asthma Regional Sales and Value Analysis
  1. 6.1 Global Biologics for Severe Asthma Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biologics for Severe Asthma Sales by Region (2021-2032)
  3. 6.2.1 Global Biologics for Severe Asthma Sales by Region: 2021-2026
  4. 6.2.2 Global Biologics for Severe Asthma Sales by Region (2027-2032)
  5. 6.3 Global Biologics for Severe Asthma Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Biologics for Severe Asthma Sales Value by Region (2021-2032)
  7. 6.4.1 Global Biologics for Severe Asthma Sales Value by Region: 2021-2026
  8. 6.4.2 Global Biologics for Severe Asthma Sales Value by Region (2027-2032)
  9. 6.5 Global Biologics for Severe Asthma Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Biologics for Severe Asthma Sales Value (2021-2032)
  12. 6.6.2 North America Biologics for Severe Asthma Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Biologics for Severe Asthma Sales Value (2021-2032)
  15. 6.7.2 Europe Biologics for Severe Asthma Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Biologics for Severe Asthma Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Biologics for Severe Asthma Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Biologics for Severe Asthma Sales Value (2021-2032)
  21. 6.9.2 South America Biologics for Severe Asthma Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Biologics for Severe Asthma Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Biologics for Severe Asthma Sales Value Share by Country, 2025 VS 2032
7 Biologics for Severe Asthma Country-level Sales and Value Analysis
  1. 7.1 Global Biologics for Severe Asthma Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biologics for Severe Asthma Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Biologics for Severe Asthma Sales by Country (2021-2032)
  4. 7.3.1 Global Biologics for Severe Asthma Sales by Country (2021-2026)
  5. 7.3.2 Global Biologics for Severe Asthma Sales by Country (2027-2032)
  6. 7.4 Global Biologics for Severe Asthma Sales Value by Country (2021-2032)
  7. 7.4.1 Global Biologics for Severe Asthma Sales Value by Country (2021-2026)
  8. 7.4.2 Global Biologics for Severe Asthma Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Biologics for Severe Asthma Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Biologics for Severe Asthma Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Biologics for Severe Asthma Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceuticals
  2. 8.1.1 Teva Pharmaceuticals Company Information
  3. 8.1.2 Teva Pharmaceuticals Business Overview
  4. 8.1.3 Teva Pharmaceuticals Biologics for Severe Asthma Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceuticals Biologics for Severe Asthma Product Portfolio
  6. 8.1.5 Teva Pharmaceuticals Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Biologics for Severe Asthma Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Biologics for Severe Asthma Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Biologics for Severe Asthma Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Biologics for Severe Asthma Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Biologics for Severe Asthma Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Roche Biologics for Severe Asthma Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Regeneron Pharmaceuticals
  26. 8.5.1 Regeneron Pharmaceuticals Company Information
  27. 8.5.2 Regeneron Pharmaceuticals Business Overview
  28. 8.5.3 Regeneron Pharmaceuticals Biologics for Severe Asthma Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Regeneron Pharmaceuticals Biologics for Severe Asthma Product Portfolio
  30. 8.5.5 Regeneron Pharmaceuticals Recent Developments
  31. 8.6 GSK
  32. 8.6.1 GSK Company Information
  33. 8.6.2 GSK Business Overview
  34. 8.6.3 GSK Biologics for Severe Asthma Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GSK Biologics for Severe Asthma Product Portfolio
  36. 8.6.5 GSK Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Biologics for Severe Asthma Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Biologics for Severe Asthma Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Amgen
  44. 8.8.1 Amgen Company Information
  45. 8.8.2 Amgen Business Overview
  46. 8.8.3 Amgen Biologics for Severe Asthma Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Amgen Biologics for Severe Asthma Product Portfolio
  48. 8.8.5 Amgen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biologics for Severe Asthma Value Chain Analysis
  2. 9.1.1 Biologics for Severe Asthma Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biologics for Severe Asthma Sales Mode & Process
  6. 9.2 Biologics for Severe Asthma Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biologics for Severe Asthma Distributors
  9. 9.2.3 Biologics for Severe Asthma Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst